Influence of Apolipoprotein E Varepsilon4 on Rates of Cognitive and Functional Decline in Mild Cognitive Impairment

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2010 Sep 4

PMID 20813342

Citations 37

Authors

Danielle C Whitehair

Abdullah Sherzai

Jennifer Emond

Rema Raman

Paul S Aisen

Ronald C Petersen

Adam S Fleisher

Affiliations

Soon will be listed here.

Abstract

Background: Apolipoprotein E varepsilon4 (APOE varepsilon4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE varepsilon4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI).

Methods: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE varepsilon4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period.

Results: APOE varepsilon4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE varepsilon4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale.

Conclusions: These findings demonstrate that APOE varepsilon4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE varepsilon4 status needs to be accounted for in treatment trials of MCI.

Citing Articles

APOEε4 Carriers Exhibit Objective Cognitive Deficits: A Cross-Sectional Study in a Single Center Trial.

Zeng Y, Du W, Zhang M, Walker A, Han Y, Ding Y Brain Sci. 2024; 14(3).

PMID: 38539669 PMC: 10969297. DOI: 10.3390/brainsci14030281.

Reduced brain activity during a working memory task in middle-aged apolipoprotein E ε4 carriers with overweight/obesity.

Drake J, Jakicic J, Rogers R, Aghjayan S, Stillman C, Donofry S Front Hum Neurosci. 2022; 16:1001229.

PMID: 36504632 PMC: 9732810. DOI: 10.3389/fnhum.2022.1001229.

APOE ε4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease.

Polsinelli A, Logan P, Lane K, Manchella M, Nemes S, Sanjay A Alzheimers Dement. 2022; 19(5):1983-1993.

PMID: 36394443 PMC: 10182251. DOI: 10.1002/alz.12831.

Positive Effect of Cognitive Training in Older Adults with Different Genotypes and COVID-19 History: A 1-Year Follow-Up Cohort Study.

Zorkina Y, Syunyakov T, Abramova O, Andryushchenko A, Andreuyk D, Abbazova E Diagnostics (Basel). 2022; 12(10).

PMID: 36292001 PMC: 9600912. DOI: 10.3390/diagnostics12102312.

Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease.

Murchison C, Jaeger B, Szychowski J, Cutter G, Roberson E, Kennedy R J Alzheimers Dis. 2022; 87(1):489-501.

PMID: 35342087 PMC: 9198753. DOI: 10.3233/JAD-215553.

References

Gauthier S . Cholinesterase inhibitors in late-stage Alzheimer's disease. Lancet Neurol. 2006; 5(6):468-9. DOI: 10.1016/S1474-4422(06)70454-9. View

Ramakers I, Visser P, Aalten P, Bekers O, Sleegers K, van Broeckhoven C . The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. Dement Geriatr Cogn Disord. 2008; 26(2):101-8. DOI: 10.1159/000144072. View

Kluger A, Ferris S, Golomb J, Mittelman M, Reisberg B . Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 2000; 12(4):168-79. DOI: 10.1177/089198879901200402. View

Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. DOI: 10.1126/science.8346443. View

Monsch A, Bondi M, Butters N, Salmon D, Katzman R, Thal L . Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol. 1992; 49(12):1253-8. DOI: 10.1001/archneur.1992.00530360051017. View

Petersen R, Smith G, Ivnik R, Tangalos E, Schaid D, Thibodeau S . Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995; 273(16):1274-8. View

Caselli R, Reiman E, Osborne D, Hentz J, Baxter L, Hernandez J . Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004; 62(11):1990-5. DOI: 10.1212/01.wnl.0000129533.26544.bf. View

ROSEN W, Mohs R, Davis K . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356. View

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

10.

Fleisher A, Sowell B, Taylor C, Gamst A, Petersen R, Thal L . Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007; 68(19):1588-95. DOI: 10.1212/01.wnl.0000258542.58725.4c. View

11.

Mohs R . The Alzheimer's Disease Assessment Scale. Int Psychogeriatr. 1996; 8(2):195-203. DOI: 10.1017/s1041610296002578. View

12.

Tierney M, Szalai J, SNOW W, Fisher R, Tsuda T, Chi H . A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996; 46(1):149-54. DOI: 10.1212/wnl.46.1.149. View

13.

Petersen R, Thomas R, Grundman M, Bennett D, Doody R, Ferris S . Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352(23):2379-88. DOI: 10.1056/NEJMoa050151. View

14.

Caselli R, Reiman E, Locke D, Hutton M, Hentz J, Hoffman-Snyder C . Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007; 64(9):1306-11. DOI: 10.1001/archneur.64.9.1306. View

15.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

16.

Tierney M, Yao C, Kiss A, McDowell I . Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005; 64(11):1853-9. DOI: 10.1212/01.WNL.0000163773.21794.0B. View

17.

Hofer S, Christensen H, Mackinnon A, Korten A, Jorm A, Henderson A . Change in cognitive functioning associated with apoE genotype in a community sample of older adults. Psychol Aging. 2002; 17(2):194-208. View

18.

Devanand D, Pelton G, Zamora D, Liu X, Tabert M, Goodkind M . Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol. 2005; 62(6):975-80. DOI: 10.1001/archneur.62.6.975. View

19.

Visser P, Verhey F, Ponds R, Cruts M, van Broeckhoven C, Jolles J . Course of objective memory impairment in non-demented subjects attending a memory clinic and predictors of outcome. Int J Geriatr Psychiatry. 2000; 15(4):363-72. DOI: 10.1002/(sici)1099-1166(200004)15:4<363::aid-gps129>3.0.co;2-4. View

20.

Mohs R, Knopman D, Petersen R, Ferris S, Ernesto C, Grundman M . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S13-21. View